12:00 AM
 | 
Sep 02, 2013
 |  BC Week In Review  |  Company News  |  Deals

Acton Pharmaceuticals, Meda deal

Meda will acquire Acton for $135 million in cash plus a $10 million near-term undisclosed development milestone. Acton is also eligible for sales-based milestones, which the company said may bring the total deal value up to $200 million. The deal is slated to close next quarter. Meda will gain Acton's Aerospan flunisolide, which is approved in the U.S. as maintenance treatment for asthma in patients at least...

Read the full 324 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >